B-I's COMBIVENT RECOMMENDED FOR COPD PATIENTS WITH CONTINUED BRONCHOSPASM
Executive Summary
B-I's COMBIVENT RECOMMENDED FOR COPD PATIENTS WITH CONTINUED BRONCHOSPASM who are on single-agent therapy by FDA's Pulmonary- Allergy Drugs Advisory Committee July 14. Boehringer Ingelheim's Combivent (ipratropium 21 mcg/albuterol 120 mcg) should be indicated for use in patients with chronic obstructive pulmonary disease "on an aerosol bronchodilator who continue to have evidence of bronchospasm and who are felt to require a second aerosol bronchodilator," the committee said. The panel voted 9-0 to recommend approval of the fixed-combination metered-dose inhaler.